SCHEMBL1390807

SCHEMBL1390807

CCOc1nc(NCc2ccco2)nc(Nc2ccc3[nH]ncc3c2)n1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.64
▸ MAPK1 P28482 4/20 0.64
▸ NPSR1 Q6W5P4 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ MEN1 O00255 1/20 0.64
▸ ALDH1A1 P00352 1/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ HTT P42858 1/20 0.54
▸ KCNH3 Q9ULD8 3/20 0.48
▸ PAK4 O96013 1/20 0.48
▸ EGFR P00533 1/20 0.47
▸ CFTR P13569 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ KDR P35968 3/20 0.44
▸ CDC7 O00311 1/20 0.43
▸ IGF1R P08069 1/20 0.43
▸ ROCK2 O75116 1/20 0.43
▸ SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391023 0.92 MAPT (0.64) MAPTMAPK1NPSR1KMT2AMEN1
SCHEMBL1391253 0.85 MAPT (0.66) MAPTMAPK1NPSR1KMT2AMEN1
SCHEMBL1390834 0.84 KMT2A (0.64) MAPTMAPK1NPSR1KMT2AMEN1
SCHEMBL10282906 0.83 MAPT (0.64) MAPTMAPK1NPSR1KMT2AMEN1
SCHEMBL1391138 0.83 MAPT (0.64) MAPTMAPK1NPSR1KMT2AMEN1
SCHEMBL1391296 0.83 MAPT (0.64) MAPTMAPK1NPSR1KMT2AMEN1
SCHEMBL1391379 0.83 MAPT (0.64) MAPTMAPK1NPSR1KMT2AMEN1
SCHEMBL10282671 0.82 MAPT (0.67) MAPTMAPK1NPSR1KMT2AMEN1
SCHEMBL10282719 0.82 MAPT (0.63) MAPTMAPK1NPSR1KMT2AMEN1
SCHEMBL1392083 0.82 MAPT (0.66) MAPTMAPK1NPSR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
EP-2231624-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF Progenics Pharmaceuticals, Inc. (US) 2010-09-29 — — EP disclosed
WO-2009091388-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF PROGENICS PHARMACEUTICALS, INC. (US) 2009-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS MAPT 3654/4885MAPK1 2676/4885NPSR1 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback